8-K: Core Scientific Supplements Merger Proxy Amid Shareholder Lawsuits

Core Scientific, Inc. filed an 8-K to provide supplemental disclosures to its merger proxy statement with CoreWeave, Inc. in response to shareholder lawsuits alleging disclosure deficiencies.

Summary

• Core Scientific, Inc. (CORZ) has filed an 8-K to provide supplemental disclosures to its proxy statement/prospectus concerning the proposed merger with CoreWeave, Inc.
• These disclosures are a voluntary response to three pending shareholder lawsuits (Barcia, Kaufmann, and Williams Complaints) and demand letters alleging deficiencies in the original merger disclosures.
• The company and CoreWeave deny the allegations but are providing the supplements to "moot disclosure claims and to avoid nuisance, potential expense and delay."
• Supplemental disclosures include updated estimated aggregate value of unvested Core Scientific RSU Awards for non-employee directors, totaling $8,515,576.
• Individual non-employee director RSU values are: Jeff Booth ($1,972,906), Jordan Levy ($1,972,906), Yadin Rozov ($1,972,906), Eric Weiss ($1,972,906), and Elizabeth Crain ($623,952).
• The filing also amends and restates tables from the "Selected Publicly Traded Companies Analysis" for both Core Scientific and CoreWeave, including updated Total Enterprise Value (TEV) and TEV/Adjusted EBITDA/EBIT multiples.
• Further supplements detail the Discounted Cash Flow Analysis methodologies used by PJT Partners for both Core Scientific and CoreWeave, including specific discount rate ranges and terminal value exit multiples.

Sentiment

Score: 5

Explanation: The filing is a neutral, procedural update to address legal challenges related to a merger. It provides clarifications rather than new operational or financial performance data, balancing the negative implication of lawsuits with the positive action of increased transparency.

Positives

• The company is proactively addressing shareholder concerns and legal challenges by providing additional disclosures, aiming to avoid further litigation and potential delays.
• The supplemental disclosures provide greater transparency regarding the financial analyses and executive compensation related to the merger.

Negatives

• The existence of multiple shareholder lawsuits and demand letters indicates significant shareholder dissatisfaction or perceived lack of transparency regarding the merger terms.
• The need for supplemental disclosures, even if voluntary, suggests that the initial proxy statement/prospectus was deemed insufficient by some stakeholders.
• The lawsuits introduce potential nuisance, expense, and delay to the merger process.

Risks

• The completion of the proposed transaction on anticipated terms or at all, and the timing thereof, including obtaining Core Scientific stockholder approval.
• Uncertainty in the value of the consideration Core Scientific stockholders would receive due to fluctuations in CoreWeave common stock market price.
• Anticipated tax treatment, unforeseen liabilities, future capital expenditures, revenues, expenses, earnings, synergies, economic performance, indebtedness, financial condition, losses, future prospects, business and management strategies for the management, expansion, and growth of the combined company's operations.
• The possibility that any anticipated benefits of the proposed transaction will not be realized or will not be realized within the expected time period.
• The ability of Core Scientific and CoreWeave to integrate their businesses successfully and to achieve anticipated synergies and value creation.
• Potential litigation relating to the proposed transaction that could be instituted against Core Scientific, CoreWeave, or their respective directors and officers.
• The risk that disruptions from the proposed transaction will harm Core Scientific's or CoreWeave's business, including current plans and operations, and divert management's time and attention on transaction-related issues.
• Potential adverse reactions or changes to business relationships resulting from the announcement or completion of the proposed transaction.
• Rating agency actions and Core Scientific's and CoreWeave's ability to access shortand long-term debt markets on a timely and affordable basis.
• Legislative, regulatory, and economic developments and actions targeting public companies in the artificial intelligence, power, data center, and crypto mining industries, and changes in local, national, or international laws, regulations, and policies affecting Core Scientific and CoreWeave.
• Potential business uncertainty, including the outcome of commercial negotiations and changes to existing business relationships during the pendency of the proposed transaction.
• Certain restrictions during the pendency of the proposed transaction that may impact Core Scientific's ability to pursue certain business opportunities or strategic transactions or otherwise operate its business.
• Acts of terrorism or outbreak of war, hostilities, civil unrest, attacks against Core Scientific or CoreWeave, and other political or security disturbances.
• Dilution caused by CoreWeave's issuance of additional shares of its securities in connection with the proposed transaction.
• The possibility that the transaction may be more expensive to complete than anticipated, including as a result of unexpected factors or events.
• The impacts of pandemics or other public health crises, including the effects of government responses on people and economies.
• Global or regional changes in the supply and demand for power and other market or economic conditions that impact demand and pricing.
• Changes in technical or operating conditions, including unforeseen technical difficulties.
• Development delays at Core Scientific and/or CoreWeave's data center sites, including any delays in the conversion of such sites from crypto mining facilities to high-performance computing sites.
• Core Scientific's ability to earn digital assets profitably and to attract customers for its high-density colocation capabilities.
• Core Scientific's ability to perform under its existing colocation agreements.
• Core Scientific's ability to maintain its competitive position in its existing operating segments.
• The impact of increases in total network hash rate.
• Core Scientific's ability to raise additional capital to continue its expansion efforts or other operations.
• Core Scientific's need for significant electric power and the limited availability of power resources.
• The potential failure in Core Scientific's critical systems, facilities, or services the company provides.
• The physical risks and regulatory changes relating to climate change.
• Potential significant changes to the method of validating blockchain transactions.
• Core Scientific's vulnerability to physical security breaches, which could disrupt operations.
• A potential slowdown in market and economic conditions, particularly those impacting high-density computing, the blockchain industry, and the blockchain hosting market.
• Price volatility of digital assets and Bitcoin in particular.
• Potential changes in the interpretive positions of the SEC or its staff with respect to digital asset mining firms.
• The likelihood that U.S. federal and state legislatures and regulatory agencies will enact laws and regulations to regulate digital assets and digital asset intermediaries.
• Changing expectations with respect to ESG policies.
• The effectiveness of Core Scientific's compliance and risk management methods.
• The adequacy of Core Scientific's sources of recovery if the digital assets held by Core Scientific are lost, stolen, or destroyed due to third-party digital asset services.
• Risks described in CoreWeave's Prospectus dated March 27, 2025, filed with the SEC on March 31, 2025, and subsequent reports on Forms 10-Q and 8-K.
• Risks described in Core Scientific's Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2025, filed with the SEC on August 8, 2025, Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the SEC on February 27, 2025, and subsequent reports on Forms 10-Q and 8-K.

Future Outlook

The filing reiterates forward-looking statements regarding the proposed merger with CoreWeave, including expectations for consummation, anticipated benefits, and potential challenges such as integration risks, litigation, and market fluctuations. It emphasizes that actual results may differ materially from these statements due to various risks.

Management Comments

• All of the defendants believe that the Matters are without merit.
• While Core Scientific and CoreWeave believe that the disclosures set forth in the proxy statement/prospectus comply fully with applicable law, to moot disclosure claims and to avoid nuisance, potential expense and delay, Core Scientific and CoreWeave have determined to voluntarily supplement the proxy statement/prospectus with the below disclosures.
• Core Scientific and CoreWeave deny all allegations in the Matters that any additional disclosure was or is required.

Industry Context

The merger between Core Scientific, a digital asset mining and high-density colocation provider, and CoreWeave, a specialized cloud provider for AI/HPC, reflects a broader industry trend of convergence between traditional data center infrastructure and the rapidly growing demand for high-performance computing resources driven by artificial intelligence. The valuation metrics presented for both companies and their peers (e.g., Equinix, Digital Realty, Microsoft, Amazon, Google) highlight the different valuation approaches and market perceptions for data center REITs, diversified cloud providers, and specialized AI/HPC infrastructure. The risks section also points to regulatory scrutiny in AI, power, data center, and crypto mining industries.

Comparison to Industry Standards

• Core Scientific's consensus TEV/Adj. EBITDA for CY2026E (19.8x) is slightly above the mean (19.3x) and median (19.4x) of selected publicly traded data center companies like Equinix (18.6x), Digital Realty (20.2x), Keppel DC REIT (20.7x), and Digital Core REIT (17.8x). This suggests a potentially higher valuation expectation for Core Scientific compared to its peers based on this metric.
• Core Scientific's consensus TEV/Adj. EBITDA for CY2027E (12.5x) is notably below the mean (17.6x) and median (17.5x) of its selected peers, indicating a projected decline in its relative valuation multiple or a more aggressive growth expectation for its EBITDA that normalizes the multiple.
• CoreWeave's consensus TEV/Adj. EBITDA for CY2026E (12.0x) and CY2027E (8.2x) are generally lower than the mean (19.5x and 13.5x respectively) and median (17.3x and 14.3x respectively) of its selected pureplay and diversified cloud peers (Oracle, Nebius, Microsoft, Amazon, Google, IBM). This could suggest a more conservative valuation or different growth profile compared to these larger, more established cloud players.
• CoreWeave's consensus TEV/Adj. EBIT for CY2027E (23.9x) is slightly above the mean (19.3x) and median (20.7x) of its selected peers, indicating a potentially higher valuation based on its earnings before interest and taxes.
• The discount rates used in the DCF analysis for Core Scientific's different business segments (Colocation Contracted: 10.00%-12.00%; Colocation Pipeline: 14.75%-16.75%; BTC Self Mining & Hosting: 19.00%-21.00%) reflect varying risk profiles, with Bitcoin mining being assigned the highest cost of capital, consistent with industry perceptions of its volatility and risk.

Legal Proceedings

• Barcia et al. vs. Booth et al. (Connecticut Superior Court, Bridgeport Judicial District, Case No. FBT-CV-25-6151837S) filed by purported stockholders of Core Scientific against Core Scientific, its board members, and CoreWeave, challenging disclosures related to the Merger.
• Kaufmann vs. Core Scientific, Inc. et al. (New York Supreme Court, New York County, Case No. 655996/2025) filed by a purported stockholder of Core Scientific against Core Scientific and its board members, challenging disclosures related to the Merger.
• Williams vs. Core Scientific, Inc. et al. (New York Supreme Court, New York County, Case No. 656010/2025) filed by a purported stockholder of Core Scientific against Core Scientific and its board members, challenging disclosures related to the Merger.
• Demand letters from purported stockholders alleging similar disclosure deficiencies.
• All complaints and demands remain pending as of October 22, 2025.
• Defendants believe the matters are without merit and deny any additional disclosure was required, but are providing supplements to moot claims and avoid nuisance, potential expense, and delay.

Stakeholder Impact

• Shareholders: Directly impacted by the merger terms and the adequacy of disclosures. The supplemental information aims to address their concerns and provide more clarity for voting decisions. The lawsuits highlight potential dissatisfaction among some shareholders.
• Management/Directors: Named as defendants in lawsuits, requiring their attention and potentially incurring legal expenses. Their unvested RSU awards are detailed as part of the merger compensation.
• CoreWeave: As the acquiring entity, it is also named in one lawsuit and is involved in providing supplemental disclosures to ensure the merger proceeds smoothly.
• Regulators (SEC): The filing is a response to regulatory requirements and shareholder scrutiny, ensuring compliance with disclosure obligations.

Next Steps

• Core Scientific stockholders will need to vote on the proposed transaction.
• The merger process will continue, subject to regulatory approvals and the resolution of any legal challenges.
• Core Scientific and CoreWeave will continue to file relevant documents with the SEC regarding the proposed transaction.

Key Dates

Keywords

Core Scientific, CoreWeave, Merger, SEC Filing, 8-K, Proxy Statement, Supplemental Disclosure, Shareholder Lawsuit, Corporate Governance, Financial Analysis, Valuation, Bitcoin Mining, Data Center, AI, High-Performance Computing, CORZ, CORZW, CORZZ